Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Because obesity and obesity-related conditions have been linked to several types of cancer, doctors believe that these ...

From going blind and suffering from life-long diarrhea to battling addiction and finding love, people who take Ozempic and other GLP-1 medications are seeing that the drugs are doing more than ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support ...

A Columbia University dermatologist argues that physicians in her specialty should be on the lookout for metabolic syndrome ...

Weight loss medications like Wegovy and Zepbound can be effective but may pose risks for older adults, including muscle loss and bone density decline.

AM Best, a global credit rating agency focused on the insurance industry, has released its Annual Review & Preview Best's ...

Why some health groups are banding together to push for a range of obesity-care options in workplace-sponsored insurance.